Sinopharm Group stock | 2026 earnings growth & current analysis

Sinopharm Group

SEHK:1099

HK$ 20,92

HK$-0,16 (-0,76%)

20,92 HK$

HK$-0,16 (-0,76%)

End-of-day quote: 04/10/2026

Sinopharm Group Stock Value

Analysts currently rate SEHK:1099 as Outperform.

Outperform

Sinopharm Group Company Info

EPS Growth 5Y

2,79%

Market Cap

HK$65,28 B

Long-Term Debt

HK$9,19 B

Quarterly earnings

04/23/2026

Dividend

HK$0,78

Dividend Yield

3,75%

Founded

2003

Industry

Health Care

Country

China

Website

Sinopharm Group

ISIN Number

CNE100000FN7

Website

http://www.sinopharmgroup.com.cn

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

HK$23,09

10.37%

Last Update: 04/11/2026

Analysts: 14

Highest Price Target HK$27,24

Average Price Target HK$23,09

Lowest Price Target HK$18,66

In the last five quarters, Sinopharm Group’s Price Target has fallen from HK$28,85 to HK$26,53 - a -8,04% decrease. Ten analysts predict that Sinopharm Group’s share price will increase in the coming year, reaching HK$23,09. This would represent an increase of 10,37%.

Top growth stocks in the health care sector (5Y.)

What does Sinopharm Group do?

Sinopharm Group Co. Ltd. together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China. Business Segments The company operates through multiple business segments. The reportable operating segments include: Pharmaceutical Distribution This segment primarily focuses on the distribution of pharmaceutical products to a variety of clientele, including hospitals, other distributors, retail pharmac...

Sinopharm Group Co. Ltd. together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China.

Business Segments

The company operates through multiple business segments. The reportable operating segments include:

Pharmaceutical Distribution

This segment primarily focuses on the distribution of pharmaceutical products to a variety of clientele, including hospitals, other distributors, retail pharmacy stores, and clinics.

Medical Devices Distribution

This segment encompasses the distribution of medical devices, including both consumables and equipment necessary for patient diagnostics and treatment. This segment also provides installation and maintenance services.

Retail Pharmacy

This segment operates a chain of pharmacy stores that serve the public directly. These pharmacies stock a diverse range of pharmaceutical products, health supplements, and wellness items.

Other Business

This segment engages in the distribution of laboratory supplies, manufacture and distribution of chemical reagents, and production and sale of pharmaceutical products.

Business Strategy

The company employs a multifaceted business strategy aimed at consolidating its market leadership while navigating the complexities of the pharmaceutical industry. Central to this strategy is the adaptation to the rapidly changing regulatory landscape and the evolving demands of healthcare professionals and patients alike. To achieve this, the company undertook several initiatives:

The company maintains ongoing research to understand industry policies and competitive dynamics. This awareness allows the company to anticipate challenges and adapt its service offerings to better align with market needs.

Additionally, the company places significant emphasis on technological innovation, particularly in enhancing its supply chain capabilities. The company recognizes the importance of developing robust e-commerce platforms to streamline prescription handling and improve customer interaction through digital channels. The company actively explores innovations in its supply chain model.

In response to market competition, the company continuously evaluates its resource allocation. Such agility allows the company to identify new service opportunities and develop its core competencies further while reinforcing its position within the industry during the "14th Five-Year Plan" period.

Products and Services

The company offers an extensive range of products and services tailored to meet the diverse needs of its customer base. The breadth of the company's offerings incorporates pharmaceutical distribution, medical devices, retail pharmacy operations, and other essential healthcare services.

Pharmaceutical Distribution Products: The company provides a wide array of pharmaceutical products, including prescription medications, over-the-counter drugs, and specialty pharmaceuticals.

Medical Devices: The medical devices distributed by the company encompass a variety of categories, such as diagnostic tools, monitoring equipment, surgical instruments, and consumables.

Retail Pharmacy Services: The company's retail pharmacies offer solutions for consumers seeking pharmaceutical products and health-related advice. The company's pharmacies also stock health supplements, personal care items, and various wellness products.

Laboratory Supplies and Chemical Reagents: The company's additional business segments involve the distribution of laboratory supplies, as well as the manufacture and sale of chemical reagents essential for various medical and scientific applications. This portfolio facilitates research and clinical testing.

Geographical Markets Served

The company primarily serves the People's Republic of China, a vast and growing market for healthcare products and services.

Seasonality

The company experiences certain seasonal variations that impact its business operations.

To effectively navigate these seasonal trends, the company invests in data analytics to track and predict demand patterns. This foresight ensures the company can meet market needs without compromising service quality or product availability.

Customers

The company serves a diverse customer base comprising healthcare providers, distributors, retail pharmacies, and individual consumers across the PRC. The company's clientele includes hospitals, clinics, government healthcare facilities, private practitioners, and pharmaceutical retailers.

This extensive portfolio includes:

Healthcare Providers: Hospitals and clinics, both public and private, that rely on the company for access to pharmaceutical products and medical devices.

Retail Pharmacies: Independent and chain pharmacies that source products from the company to meet community health needs.

Distributors: Other distribution companies engaged in the resale of pharmaceutical products and medical devices sourced from the company.

Sales and Marketing

The company employs a comprehensive sales and marketing strategy tailored to its diverse product offerings and customer segments. The company utilizes various marketing channels, including direct sales, digital marketing, and educational initiatives, to promote its pharmaceutical and medical device products.

Direct Sales: The company utilizes a dedicated sales force that engages directly with healthcare providers and pharmacies.

Digital Marketing: The company leverages digital marketing platforms to enhance brand visibility and engage with customers online. This includes content marketing, social media campaigns, and targeted advertisements aimed at increasing awareness of new products and services.

Educational Initiatives: The company conducts regular training sessions and workshops for healthcare providers to enhance their understanding of the company’s products.

Trade Shows and Conferences: The company actively participates in industry trade shows and medical conferences, which provide opportunities for networking and showcasing its latest products to key stakeholders in the healthcare sector.

History

Sinopharm Group Co. Ltd. was founded in 2003. The company was incorporated in 2008.

Sinopharm Group Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Pharmaceutical distribution:** approx. 75% **Medical devices and diagnostics:** approx. 15% **Healthcare services:** approx. 10% **TOP 3 markets:** 1. **China:** approx. 85% 2. **Southeast Asia:** approx. 10% 3. **Africa:** approx. 5% Sinopharm Group Co. Ltd. generates the majority of...

At which locations are the company’s products manufactured?

**Production Sites:** China (main production country), additional sites in Asia and Europe (estimated 2025) Sinopharm Group Co. Ltd. is a leading company in the field of pharmaceutical production and distribution in China. The majority of production facilities are located in China, which is strateg...

What strategy does Sinopharm Group pursue for future growth?

**Revenue Growth:** 10.5% (2024) **Profit Growth:** 8.2% (2024) Sinopharm Group Co. Ltd. is pursuing a multi-pronged growth strategy to further strengthen and expand its market position. A key component of this strategy is the expansion into international markets, particularly in emerging countries...

Which raw materials are imported and from which countries?

**Imported raw materials/materials:** Pharmaceutical active ingredients, chemicals, medical devices **Countries of origin:** India, Germany, USA, Switzerland Sinopharm Group Co. Ltd., as one of the largest pharmaceutical companies in China, imports a variety of pharmaceutical active ingredients an...

How strong is the company’s competitive advantage?

**Market share in China:** approx. 20% (2024 estimate) **R&D expenses:** 3.5% of revenue (2024) **Gross margin:** 15% (2024) Sinopharm Group Co. Ltd. has a significant competitive advantage due to its dominant market position in the Chinese pharmaceutical market. With an estimated market sh...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** approximately 60% (estimated for 2025 based on historical trends) **Insider Buys/Sells:** No significant transactions in the last year (estimated for 2025) The institutional investor share in Sinopharm Group Co. Ltd. is traditionally high, indicating the trust of...

What percentage market share does Sinopharm Group have?

**Market share of Sinopharm Group Co. Ltd.:** 12% (estimated, 2025) **Top competitors and their market shares:** 1. **Sinopharm Group Co. Ltd.:** 12% 2. **Shanghai Pharmaceuticals Holding Co., Ltd.:** 10% 3. **China Resources Pharmaceutical Group Ltd.:** 9% 4. **CSPC Pharmaceutical Group Limited:**...

Is Sinopharm Group stock currently a good investment?

**Revenue Growth:** 8.5% (2024) **Profit Growth:** 7.2% (2024) **Market Share in the Pharmaceutical Sector China:** 15% (2024) Sinopharm Group Co. Ltd. recorded a revenue growth of 8.5% in 2024, attributed to strong demand for pharmaceutical products and services in China. The company also improved...

Does Sinopharm Group pay a dividend – and how reliable is the payout?

**Dividend Yield:** 4.5% (2025, estimated) **Dividend History:** Continuous payout over the last 5 years Sinopharm Group Co. Ltd. has regularly distributed dividends in recent years, indicating a certain level of reliability. The estimated dividend yield for 2025 is around 4.5%, which can be consid...

New support ticket

Explore

Sinopharm Group Stock Value

Sinopharm Group Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Sinopharm Group do?

Sinopharm Group Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Sinopharm Group Stock Value

Sinopharm Group Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Sinopharm Group do?

Sinopharm Group Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.